A randomized, double-blind, placebo-controlled study of oral hydrolytic enzymes in relapsing multiple sclerosis.
Oral administration of hydrolytic enzymes (HE), such as bromelain, trypsin and rutosid, may have beneficial effects on the clinical course of neurological symptoms related to multiple sclerosis (MS). This is supported by a complete protection by HE from experimental allergic encephalomyelitis, an animal model related to MS. Three hundred and one patients with relapsing MS were enrolled in a double-blind, placebo-controlled trial. No treatment effect between the placebo and the HE groups was found either for clinical or MRI parameters.
Baumhackl
U
U
Department of Neurology, Central Clinic, St Poelten, Austria. neurologie@kh-st-poelten.at
Kappos
L
L
Radue
E W
EW
Freitag
P
P
Guseo
A
A
Daumer
M
M
Mertin
J
J
D000284:Administration, Oral; D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage*; D001963:Bromelains / Q000008:administration & dosage*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy* / Q000473:pathology; D010919:Placebos; D012008:Recurrence; D012431:Rutin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D016896:Treatment Outcome; D014357:Trypsin / Q000008:administration & dosage*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D010919:Placebos; C056067:rutin sulfate; D012431:Rutin; D001963:Bromelains; D014357:Trypsin